Implementation of Pharmacogenetic Testing as Part of Medication Reviews in Hospital Wards
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 46
- 试验地点
- 2
- 主要终点
- Number of patients with results from pharmacogenetic testing included in medication review
研究概览
简要总结
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.
详细描述
Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone.
The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward.
The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •at least 2 long-term conditions
- •at least 5 regular drugs of which at least one relevant for pharmacogenetic testing
- •at least 2 years life expectancy
- •able to communicate in Norwegian
- •able to give informed consent
- •summary care record
排除标准
- •moderate to severe dementia
结局指标
主要结局
Number of patients with results from pharmacogenetic testing included in medication review
时间窗: from admission to discharge, an average of 1 week
Number of patients
次要结局
- Acceptance of recommendations(after medication review and before discharge, an average of 3 days)
- Documentation of information from pharmacogenetic testing(after medication review and before discharge, an average of 3 days)